415967-79-2

Basic information

• Product Name: Morpholine, 4-[1-(phenylmethyl)-4-piperidinyl]-
• Synonyms: 1-Benzyl-4-morpholinopiperidin;4-[1-(phenylmethyl)-4-piperidinyl]-morpholine;4-(morpholin-4-yl)-1-benzylpiperidine
• CAS NO: 415967-79-2
• Molecular Formula: C16H24N2O
• Molecular Weight: 260.379
• Mol File: 415967-79-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Morpholine, 4-[1-(phenylmethyl)-4-piperidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholine, 4-[1-(phenylmethyl)-4-piperidinyl]-(415967-79-2)
• EPA Substance Registry System: Morpholine, 4-[1-(phenylmethyl)-4-piperidinyl]-(415967-79-2)

Safety Data

• Hazardous Substances Data: 415967-79-2(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 53617-35-9 4-(piperidin-4-yl)morpholine 

Relevant articles and documents

METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE

The object of the present invention is to provide a method for preparing 4-(piperidin-4-yl)morpholine, which is easy to operate. The object can be solved by a method for preparing 4-(1-benzylpiperidin-4-yl)morpholine, characterized in that 5-fold molar or more of morpholine is added to 1-benzyl-4-piperidone, and the mixture is reacted with hydrogen under 1 MPa or less in the presence of platinum catalyst or palladium catalyst.

Production Method

The present invention relates to a process for preparing compounds of general formula I wherein R1 and R2 are defined as in claim 1, the pharmaceutically acceptable salts and the solvates thereof, which may be prepared starting from compounds of general formula II wherein R1 is defined as in claim 1.

5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular met kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.